Physician profile
Clovis E Manley
NPI 1336212331
$1,779.43
in general payments reported to CMS, 2019-2025
26 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $236 · 2021: $228 · 2022: $334 · 2023: $399 · 2024: $169 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.58 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.18 | 2021-2025 | |
| Medtronic, INC. | $182.01 | 2022-2025 | Venaseal, Closurefast |
| Tactile Systems Technology INC | $171.11 | 2019-2024 | Entre Plus, Flexitouch Plus |
| Novo Nordisk INC | $136.37 | 2019-2023 | Ozempic, Rybelsus |
| Allergan, INC. | $111.01 | 2019-2022 | |
| Inspire Medical Systems, INC. | $92.52 | 2025 | Inspire |
| Biocompatibles, INC. | $90.19 | 2019 | |
| Lilly USA, LLC | $78.32 | 2020-2022 | |
| Boston Scientific Corporation | $71.82 | 2020-2022 | |
| Glaxosmithkline, LLC. | $67.37 | 2020-2021 | |
| Amgen INC. | $59.68 | 2020-2023 | Prolia, Evenity |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.04 | 2022 | |
| Dexcom, INC. | $32.24 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $32.10 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.52 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $28.72 | 2022 | |
| Triad Life Sciences INC. | $18.81 | 2022 | |
| Angiodynamics, INC. | $18.58 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.35 | 2024 | Xarelto |
| Astellas Pharma US INC | $16.21 | 2023 | Myrbetriq |
| Alnylam Pharmaceuticals INC. | $14.74 | 2024 | Onpattro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.39 | 2021 | |
| Hologic Sales and Service, LLC | $13.19 | 2023 | Aptima |
| Smith+Nephew, INC. | $12.99 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $11.91 | 2020 | |
| Prugen, INC. Pharmaceuticals | $9.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clovis Manley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.